Bristol-Myers Squibb Co
NYSE:BMY
Relative Value
The Relative Value of one BMY stock under the Base Case scenario is 78.0875 USD. Compared to the current market price of 45.0897 USD, Bristol-Myers Squibb Co is Undervalued by 42%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
BMY Competitors Multiples
Bristol-Myers Squibb Co Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Bristol-Myers Squibb Co
NYSE:BMY
|
91.1B USD | 2 | 11.4 | 5.6 | 10.7 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
696B USD | 20.4 | 132.8 | 60 | 68.9 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 17 | 47.1 | 34.5 | 37.6 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | 9 733.7 | 1 771.8 | 4 320.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
352.9B USD | 4.3 | 8.7 | 11.6 | 15.3 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.6B USD | 5.5 | 911.2 | 45.2 | 88.3 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
185.5B GBP | 5 | 38.8 | 140.4 | 225.3 | ||
CH |
Novartis AG
SIX:NOVN
|
183.1B CHF | 4.3 | 13.5 | 9.9 | 16.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
176.4B CHF | 3 | 15.3 | 8.5 | 10 |